FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999962016> ?p ?o ?g. }

• W1999962016 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLPurpose: Previous reports demonstrate that chloropyramine has anti-tumor efficacy as a single agent, and in combination with cytotoxic agents like doxorubicin through modulation of the FAK-VEGFR-3 pathway. Since limited information is available about the pharmacokinetics of chloropyramine, we investigated the pharmacokinetics and tissue distribution of the drug following a single intraperitoneal (IP) injection.Methods: Female CD-1 mice received a single 50mg/kg dose of chloropyramine; plasma and tissue samples were collected at serial timepoints of 0.5, 1.0, 2.0, 4.0, and 6.0 hours. The tissues included brain, heart, spleen, liver, lung, muscle, and sternum. Each timepoint contained three mice. Chloropyramine concentrations were determined in both plasma and tissues, using a validated LC-MS/MS. Assay was validated with an LLOQ of 0.25ng/ml with the calibration curve ranging from 0.25-100ng/ml (3.42-12.4%CV). Noncompartmental PK analysis was performed using WinNonlin (Pharsight, Version 5.3). Pharmacokinetic parameters including: Maximal concentration (Cmax), terminal elimination half life (T1/2), area under the curve (AUC0-6hr), apparent clearance (Cl/F), apparent volume of distribution (Vd/F), and partition coefficients (Kp).Results: Following IP injection, chloropyramine followed either a mono- or bi-exponential decay in both plasma and tissues. Chloropyramine is cleared from plasma and all tissues within 12hr; thus chloropyramine does not exhibit a great potential for accumulation. Cmax was achieved within 1.0 hour for plasma and all tissues. Chloropyramine distributes well into various tissues such as the spleen, liver, lung, kidney, brain, and heart. The highest level of chloropyramine was achieved in lung tissue with a mean (sd) Cmax concentrations of 41.6 (11.6) μg/ml, respectively. In contrast, the mean Cmax in plasma was approximately 0.5 μg/ml; much less compared to tissues. The mean T1/2 was 0.83 (0.19) hr. The lungs exhibited the highest total tissue penetration of chloropyramine, representing a mean AUC of 51.3 μg-hr/g. The least total exposure was in muscle, with a mean AUC of 8.5 μg-hr/g. The apparent CL/F from plasma was 28.5 L/hr/kg while it was 0.9 L/hr/kg for lung tissue.Conclusions: These results illustrate the wide tissue distribution of chloropyramine, despite of the short plasma half-life. In addition, these results are of great importance because it provides supportive evidence of the tissue levels that will lead to anti-tumor efficacy through inhibition of FAK and VEGFR-3. Thus, evaluation of plasma and tissue concentrations of the drug elucidates the pharmacokinetics of this compound in an effort to identify target tissues into which it has a high degree of penetration to maximize antitumor efficacy.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4257. doi:10.1158/1538-7445.AM2011-4257" @default.
• W1999962016 created "2016-06-24" @default.
• W1999962016 creator A5013736647 @default.
• W1999962016 creator A5024475539 @default.
• W1999962016 creator A5049273530 @default.
• W1999962016 creator A5052141297 @default.
• W1999962016 creator A5062284417 @default.
• W1999962016 creator A5063922934 @default.
• W1999962016 creator A5074178460 @default.
• W1999962016 creator A5085657580 @default.
• W1999962016 creator A5088762890 @default.
• W1999962016 date "2011-04-15" @default.
• W1999962016 modified "2023-09-25" @default.
• W1999962016 title "Abstract 4257: Pharmacokinetics (PK) and tissue penetration of the novel VEGFR-3/FAK inhibitor, Chloropyramine" @default.
• W1999962016 doi "https://doi.org/10.1158/1538-7445.am2011-4257" @default.
• W1999962016 hasPublicationYear "2011" @default.
• W1999962016 type Work @default.
• W1999962016 sameAs 1999962016 @default.
• W1999962016 citedByCount "1" @default.
• W1999962016 countsByYear W19999620162014 @default.
• W1999962016 crossrefType "proceedings-article" @default.
• W1999962016 hasAuthorship W1999962016A5013736647 @default.
• W1999962016 hasAuthorship W1999962016A5024475539 @default.
• W1999962016 hasAuthorship W1999962016A5049273530 @default.
• W1999962016 hasAuthorship W1999962016A5052141297 @default.
• W1999962016 hasAuthorship W1999962016A5062284417 @default.
• W1999962016 hasAuthorship W1999962016A5063922934 @default.
• W1999962016 hasAuthorship W1999962016A5074178460 @default.
• W1999962016 hasAuthorship W1999962016A5085657580 @default.
• W1999962016 hasAuthorship W1999962016A5088762890 @default.
• W1999962016 hasConcept C110121322 @default.
• W1999962016 hasConcept C112705442 @default.
• W1999962016 hasConcept C126322002 @default.
• W1999962016 hasConcept C126894567 @default.
• W1999962016 hasConcept C134306372 @default.
• W1999962016 hasConcept C138944611 @default.
• W1999962016 hasConcept C139254425 @default.
• W1999962016 hasConcept C185592680 @default.
• W1999962016 hasConcept C22979827 @default.
• W1999962016 hasConcept C2780091579 @default.
• W1999962016 hasConcept C33923547 @default.
• W1999962016 hasConcept C71924100 @default.
• W1999962016 hasConcept C76318530 @default.
• W1999962016 hasConcept C98274493 @default.
• W1999962016 hasConceptScore W1999962016C110121322 @default.
• W1999962016 hasConceptScore W1999962016C112705442 @default.
• W1999962016 hasConceptScore W1999962016C126322002 @default.
• W1999962016 hasConceptScore W1999962016C126894567 @default.
• W1999962016 hasConceptScore W1999962016C134306372 @default.
• W1999962016 hasConceptScore W1999962016C138944611 @default.
• W1999962016 hasConceptScore W1999962016C139254425 @default.
• W1999962016 hasConceptScore W1999962016C185592680 @default.
• W1999962016 hasConceptScore W1999962016C22979827 @default.
• W1999962016 hasConceptScore W1999962016C2780091579 @default.
• W1999962016 hasConceptScore W1999962016C33923547 @default.
• W1999962016 hasConceptScore W1999962016C71924100 @default.
• W1999962016 hasConceptScore W1999962016C76318530 @default.
• W1999962016 hasConceptScore W1999962016C98274493 @default.
• W1999962016 hasLocation W19999620161 @default.
• W1999962016 hasOpenAccess W1999962016 @default.
• W1999962016 hasPrimaryLocation W19999620161 @default.
• W1999962016 hasRelatedWork W1479425248 @default.
• W1999962016 hasRelatedWork W163853733 @default.
• W1999962016 hasRelatedWork W1980087735 @default.
• W1999962016 hasRelatedWork W2041959295 @default.
• W1999962016 hasRelatedWork W2053198377 @default.
• W1999962016 hasRelatedWork W2084402116 @default.
• W1999962016 hasRelatedWork W2092052285 @default.
• W1999962016 hasRelatedWork W2107525821 @default.
• W1999962016 hasRelatedWork W2279192913 @default.
• W1999962016 hasRelatedWork W2366814817 @default.
• W1999962016 hasRelatedWork W2370007884 @default.
• W1999962016 hasRelatedWork W2390061060 @default.
• W1999962016 hasRelatedWork W2400973727 @default.
• W1999962016 hasRelatedWork W2418220561 @default.
• W1999962016 hasRelatedWork W2501735448 @default.
• W1999962016 hasRelatedWork W2741832897 @default.
• W1999962016 hasRelatedWork W2768333772 @default.
• W1999962016 hasRelatedWork W2885468960 @default.
• W1999962016 hasRelatedWork W2897057358 @default.
• W1999962016 hasRelatedWork W3083107551 @default.
• W1999962016 isParatext "false" @default.
• W1999962016 isRetracted "false" @default.
• W1999962016 magId "1999962016" @default.
• W1999962016 workType "article" @default.